-
B0396-1 mg
Inhibitor of p110a PI3K. It induces cell cycle arrest and apoptosis in multiple myeloma cells. (C003B-255000)
Price: $197.64List Price: $219.60BAY80-6946 is an inhibitor of p110a PI3K that exhibits anticancer chemotherapeutic activity. BAY80-6946 is currently in clinical trials and shows some benefit in the treatment of pancreatic cancer. -
B0396-5 mg
Inhibitor of p110a PI3K. It induces cell cycle arrest and apoptosis in multiple myeloma cells. (C003B-255611)
Price: $516.81List Price: $574.23BAY80-6946 is an inhibitor of p110a PI3K that exhibits anticancer chemotherapeutic activity. BAY80-6946 is currently in clinical trials and shows some benefit in the treatment of pancreatic cancer. -
B0396-10 mg
Inhibitor of p110a PI3K. It induces cell cycle arrest and apoptosis in multiple myeloma cells. (C003B-255865)
Price: $788.47List Price: $876.07BAY80-6946 is an inhibitor of p110a PI3K that exhibits anticancer chemotherapeutic activity. BAY80-6946 is currently in clinical trials and shows some benefit in the treatment of pancreatic cancer. -
I339506-100mg
Iron Chelator, Dp44mT (C007B-195913)
Price: $306.20List Price: $340.22Product Describtion:Iron Chelator, Dp44mT is a cell-permeable di-2-pyridyl thiosemicarbazone (DpT) based tridentate ligand that displays potent and selective antiproliferative properties in neoplastic cells and minimally affects normal cells. Iron -
I339506-25mg
Iron Chelator, Dp44mT (C007B-195914)
Price: $136.56List Price: $151.73Product Describtion:Iron Chelator, Dp44mT is a cell-permeable di-2-pyridyl thiosemicarbazone (DpT) based tridentate ligand that displays potent and selective antiproliferative properties in neoplastic cells and minimally affects normal cells. Iron -
I339506-500mg
Iron Chelator, Dp44mT (C007B-195915)
Price: $1,297.58List Price: $1,441.76Product Describtion:Iron Chelator, Dp44mT is a cell-permeable di-2-pyridyl thiosemicarbazone (DpT) based tridentate ligand that displays potent and selective antiproliferative properties in neoplastic cells and minimally affects normal cells. Iron -
I655888-1ml
IST5-002 (C007B-362583)
Price: $817.18List Price: $907.97IST5-002, a potent Stat5a/b inhibitor, selectively inhibits transcriptional activity of Stat5a/b ( IC 50 s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) -
B5000-1 mg
JAK2 inhibitor. It inhibits cell proliferation in models of myeloproliferative neoplasms. (C003B-255278)
Price: $345.46List Price: $383.84BMS-911543 is an oral selective inhibitor of JAK2 currently in clinical trials. BMS-911543 shows anticancer activity through inhibition of the JAK/STAT signaling cascade in in vitro and in vivo models of myeloproliferative neoplasms, which display -
B5000-5 mg
JAK2 inhibitor. It inhibits cell proliferation in models of myeloproliferative neoplasms. (C003B-255804)
Price: $724.48List Price: $804.97BMS-911543 is an oral selective inhibitor of JAK2 currently in clinical trials. BMS-911543 shows anticancer activity through inhibition of the JAK/STAT signaling cascade in in vitro and in vivo models of myeloproliferative neoplasms, which display -
J649504-1mg
JAK2-IN-6 (C007B-363017)
Price: $101.80List Price: $113.11JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC 50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3 . JAK2-IN-6 has anti-proliferative effect against cancer cellsIn -
J649504-5mg
JAK2-IN-6 (C007B-363018)
Price: $191.94List Price: $213.27JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC 50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3 . JAK2-IN-6 has anti-proliferative effect against cancer cellsIn -
J651882-10mg
JAK2/FLT3-IN-1 (C007B-363094)
Price: $1,521.36List Price: $1,690.41JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2 , FLT3 , JAK1 and JAK3 , respectively. JAK2/FLT3-IN-1 has anti-cancer activityIn VitroJAK2/FLT3-IN-1 (0.008-1 μM: for 2